These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 3733375)
21. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. Hurwitz CA; Relling MV; Weitman SD; Ravindranath Y; Vietti TJ; Strother DR; Ragab AH; Pratt CB J Clin Oncol; 1993 Dec; 11(12):2324-9. PubMed ID: 7902425 [TBL] [Abstract][Full Text] [Related]
22. Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas. Miller TP; Jones SE; Alberts DS; Mackel C Invest New Drugs; 1984; 2(1):75-7. PubMed ID: 6469502 [TBL] [Abstract][Full Text] [Related]
23. Phase II trial of bisantrene in non-small cell lung cancer. Miller TP; Ahmann FR; Mackel C; Greenberg BR; Alberts DS Invest New Drugs; 1985; 3(4):393-5. PubMed ID: 4086247 [TBL] [Abstract][Full Text] [Related]
24. A phase II study of bisantrene in malignant lymphomas. A Southwest Oncology Group Study. Miller TP; Cowan JD; Neilan BA; Jones SE Cancer Chemother Pharmacol; 1986; 16(1):67-9. PubMed ID: 3940222 [TBL] [Abstract][Full Text] [Related]
25. Characterization of the pharmacokinetics of bisantrene (NSC-337766). Kuhn JG; Ludden TM; Myers JW; Von Hoff DD Invest New Drugs; 1983; 1(3):253-7. PubMed ID: 6678875 [TBL] [Abstract][Full Text] [Related]
26. Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule. Adamson PC; Balis FM; Miser J; Arndt C; Wells RJ; Gillespie A; Aronson L; Penta JS; Clendeninn NJ; Poplack DG Cancer Res; 1992 Feb; 52(3):521-4. PubMed ID: 1732038 [TBL] [Abstract][Full Text] [Related]
27. Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule. Adamson PC; Balis FM; Miser J; Wells RJ; Bleyer WA; Williams TE; Gillespie A; Penta JS; Clendeninn NJ; Poplack DG Cancer Res; 1990 Aug; 50(15):4464-7. PubMed ID: 2369724 [TBL] [Abstract][Full Text] [Related]
28. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. Daw NC; Furman WL; Stewart CF; Iacono LC; Krailo M; Bernstein ML; Dancey JE; Speights RA; Blaney SM; Croop JM; Reaman GH; Adamson PC; J Clin Oncol; 2005 Sep; 23(25):6172-80. PubMed ID: 16135484 [TBL] [Abstract][Full Text] [Related]
29. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). Cowan JD; Osborne CK; Neidhart JA; Von Hoff DD; Constanzi JJ; Vaughn CB Invest New Drugs; 1985; 3(2):149-52. PubMed ID: 3894277 [TBL] [Abstract][Full Text] [Related]
30. Phase II evaluation of bisantrene in acute leukemia. A Southwest Oncology Group Study. Mills GM; Dahlberg S; Cowan J; Neilan BA; Gumbart CH; Hussein K; Coltman CA Am J Clin Oncol; 1989 Dec; 12(6):507-10. PubMed ID: 2589232 [TBL] [Abstract][Full Text] [Related]
31. Bisantrene, an active new drug in the treatment of metastatic breast cancer. Yap HY; Yap BS; Blumenschein GR; Barnes BC; Schell FC; Bodey GP Cancer Res; 1983 Mar; 43(3):1402-4. PubMed ID: 6825109 [TBL] [Abstract][Full Text] [Related]
32. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246 [TBL] [Abstract][Full Text] [Related]
33. Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study. Stiff PJ; Sweet D; Kilton LJ; Johnson CM; Muntean B; Blough RR Med Pediatr Oncol; 1991; 19(2):126-8. PubMed ID: 2011097 [TBL] [Abstract][Full Text] [Related]
34. In vivo and in vitro metabolism of the new anticancer drug bisantrene. Peng YM; Alberts DS; Davis TP Cancer Chemother Pharmacol; 1985; 14(1):15-20. PubMed ID: 3965156 [TBL] [Abstract][Full Text] [Related]
35. Phase I study of bisantrene in acute nonlymphoblastic leukemia. Marty M; Ferme C; Gisselbrecht C; Guy H; Clark MJ; Bancillon A; Boiron M Cancer Treat Rep; 1985 Jun; 69(6):703-5. PubMed ID: 4016773 [TBL] [Abstract][Full Text] [Related]
36. Bisantrene hydrochloride in gastric adenocarcinoma: a Southwest Oncology Group Study. Panettiere FJ; Jones SE; Oishi N; Eyre HJ; O'Bryan RM; Andes WA; Taylor SA; Grozea PN Med Pediatr Oncol; 1986; 14(2):78-80. PubMed ID: 3713640 [TBL] [Abstract][Full Text] [Related]
37. Directed intravascular precipitation of bisantrene for pelvic malignant lesions: preclinical studies. Lieber MM; Welch TJ; Johnson CM; Farrow GM; Buck M; Kovach JS Mayo Clin Proc; 1986 Mar; 61(3):173-9. PubMed ID: 3945117 [TBL] [Abstract][Full Text] [Related]
38. Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy. Furman WL; Rodman JH; Tonda ME; Luo X; Arnold B; Marina N; Garrison L; Hanna R; Pratt CB; Meyer WH Cancer Chemother Pharmacol; 1998; 41(3):229-36. PubMed ID: 9443640 [TBL] [Abstract][Full Text] [Related]
39. Activity of bisantrene in refractory lymphoma. McLaughlin P; Cabanillas F; Hagemeister FB; Velasquez WS Cancer Treat Rep; 1987 Jun; 71(6):631-3. PubMed ID: 3581102 [TBL] [Abstract][Full Text] [Related]
40. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]